Coronavirus Replication and Protease Inhibitor

Program Discovery Preclinical Phase 1 Phase 2a Phase 3
Coronavirus (COVID-19) Replication and Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started

On February 24, 2020 the Company announced that it had entered into a license agreement with Kansas State University Research Foundation (KSURF) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections. On April 22, 2020 Cocrystal announced it expanded its previously announced license agreement with KSURF to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds for the treatment of coronavirus infections (COVID-19).

Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain small molecule therapeutic inhibitors against coronaviruses, picornaviruses and caliciviruses covered by patent rights controlled by KSURF. Cocrystal intends to pursue research and development of these antiviral compounds for coronavirus, including preclinical and clinical development. This license significantly expands and further advances the Company's COVID-19 program by providing more targeted, potent compounds for further development.

The additional compounds licensed from KSURF have demonstrated both in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are coronaviruses that are structurally similar to SARS-CoV-2.

We initiated preclinical studies of COVID-19 inhibitors during the second quarter of 2020 and plan to identify additional COVID-19 inhibitors utilizing our proprietary platform technology during the third quarter of this year. We anticipate the selection of a lead preclinical molecule in the fourth quarter of 2020.